Virtual Library

Start Your Search

Marclesson Alves

Author of

  • +

    P3.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 983)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.17-01 - PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients from Brazil (ID 12971)

      12:00 - 13:30  |  Presenting Author(s): Marclesson Alves

      • Abstract


      Despite the importance of the mutational profile to outcomes in non-small cell lung cancer (NSCLC), there is limited data describing the prevalence of molecular alterations such as ALK translocations, EGFR mutational status and programmed death-ligant 1 (PD-L1) expression in tumors from Brazil. The aim of this study was to investigate the mutational profile of lung adenocarcinoma of specimens from Brazil and correlation between high PD-L1 expression in NSCLCs with known driver oncogenes ALK and EGFR

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We retrospectively evaluated PD-L1 expression in 132 surgically resected primary lung adenocarcinoma including 57 with EGFR status mutation and 121 with ALK expression. PD-L1 and ALK expression were evaluated by immunohistochemical analysis with the SP263 and D5F3 assays, respectively. EGFR mutation status was assessed by sequencing.

      4c3880bb027f159e801041b1021e88e8 Result

      Of the 132 samples analyzed, 2 (1.5%) had a PD-L1 tumor proportion score (TPS) of 1%–4%, 31 (23,5%) had a PD-L1 TPS of 5%–49% and 20 (15.2%) ≥50%. ALK expression was detected in 18 (14.9%) of the 121 tumor samples and 3 (16.7%) of them had a PD-L1 TPS of ≥50%. Forty-two (73.7%) patients had wild-type EGFR, and 15 (26.3%) had mutant EGFR being exon 21 L858R and exon 19 deletion the most frequent mutation. Of the 15 tumors with EGFR mutations, 11 (73.3%) did not express PD-L1 and 4 (26.7%) had a PD-L1 TPS of 1%–49%

      8eea62084ca7e541d918e823422bd82e Conclusion

      Considering that a subset of patients with ALK expression had a PD-L1 TPS of ≥50%, further studies will be required to examine the efficacy of PD-1/PD-L1 inhibitors in such patients.